(5a<I>R</I>,10b<I>S</I>)-5a,10b-二氢-2-(2,4,6-三甲苯基)-4<I>H</I>,6<I>H</I>-茚并[2,1-<I>b</I>]-1,2,4-三唑并[4,3-<I>d</I>]-1,4-噁嗪鎓氯化物 CAS 903571-02-8

(+)-(5aR,10bS)-5a,10b-Dihydro-2-(2,4,6-trimethylphenyl)-4H,6H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Chloride (+)-(5aR,10bS)-5a,10b-Dihydro-2-mesityl-4H,6H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Chloride 903571-02-8 Bode Catalyst 2 D3983

纯度 97%+现货药物标准品
CAS 号903571-02-8
分子式C21H38N3O Cl
分子量N/A g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

(5a<I>R</I>,10b<I>S</I>)-5a,10b-二氢-2-(2,4,6-三甲苯基)-4<I>H</I>,6<I>H</I>-茚并[2,1-<I>b</I>]-1,2,4-三唑并[4,3-<I>d</I>]-1,4-噁嗪鎓氯化物 (+)-(5aR,10bS)-5a,10b-Dihydro-2-(2,4,6-trimethylphenyl)-4H,6H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Chloride (+)-(5aR,10bS)-5a,10b-Dihydro-2-mesityl-4H,6H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Chloride 903571-02-8 Bode Catalyst 2 D3983 CAS 903571-02-8 结构式 Chemical Structure

产品介绍 Description

本产品为药物标准品(5a<I>R</I>,10b<I>S</I>)-5a,10b-二氢-2-(2,4,6-三甲苯基)-4<I>H</I>,6<I>H</I>-茚并[2,1-<I>b</I>]-1,2,4-三唑并[4,3-<I>d</I>]-1,4-噁嗪鎓氯化物（(+)-(5aR,10bS)-5a,10b-Dihydro-2-(2,4,6-trimethylphenyl)-4H,6H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Chloride (+)-(5aR,10bS)-5a,10b-Dihydro-2-mesityl-4H,6H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Chloride 903571-02-8 Bode Catalyst 2 D3983，CAS 903571-02-8），分子式 C21H38N3O Cl。纯度 97%+。适用于分析方法开发、方法验证及日常质检，CATO 提供全程冷链与全球配送。

与同类药物标准品相比，(5a<I>R</I>,10b<I>S</I>)-5a,10b-二氢-2-(2,4,6-三甲苯基)-4<I>H</I>,6<I>H</I>-茚并2,1-<I>b</I>-1,2,4-三唑并4,3-<I>d</I>-1,4-噁嗪鎓氯化物的分子量为384.00 g/mol这一特征使其在色谱分离条件和质谱检测参数设置上具有独特性。 (5a<I>R</I>,10b<I>S</I>)-5a,10b-二氢-2-(2,4,6-三甲苯基)-4<I>H</I>,6<I>H</I>-茚并2,1-<I>b</I>-1,2,4-三唑并4,3-<I>d</I>-1,4-噁嗪鎓氯化物（(+)-(5aR,10bS)-5a,10b-Dihydro-2-(2,4,6-trimethylphenyl)-4H,6H-indeno2,1-b1,2,4triazolo4,3-d1,4oxazinium Chloride (+)-(5aR,10bS)-5a,10b-Dihydro-2-mesityl-4H,6H-indeno2,1-b1,2,4triazolo4,

应用场景：(5a<I>R</I>,10b<I>S</I>)-5a,10b-二氢-2-(2,4,6-三甲苯基)-4<I>H</I>,6<I>H</I>-茚并 2,1-<I>b</I> -1,2,4-三唑并 4,3-<I>d</I> -1,4-噁嗪鎓氯化物（(+)-(5aR,10bS)-5a,10b-Dihydro-2-(2,4,6-trimethylphenyl)-4H,6H-indeno 2,1-b 1,2,4 triazolo 4,3-d 1,4 oxazinium Chloride (+)-(5aR,10bS)-5a,10b-Dihydro-2-mesityl-4H,6H-indeno 2,1-

理化性质 Physical & Chemical Properties

中文名称(5a<I>R</I>,10b<I>S</I>)-5a,10b-二氢-2-(2,4,6-三甲苯基)-4<I>H</I>,6<I>H</I>-茚并[2,1-<I>b</I>]-1,2,4-三唑并[4,3-<I>d</I>]-1,4-噁嗪鎓氯化物
分子式C21H38N3O Cl
分子量384.00 g/mol
外观形态类白色至淡黄色结晶性粉末。（具有轻微卤代物特征气味）
纯度97%+
储存条件2-8°C冷藏保存，避光
溶解性参考可溶于DMSO、DMF、甲醇
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）4.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1987年
卤素含量Cl取代
含氮原子数3

相关专利 Related Patents

  1. 发明人马晓峰，周伟，何建平. "一种(5a<I>R</I>,10b<I>S</I>)-5a,10b-二氢-2-(2,4,6-三甲苯基)-4<I>H</I>,6<I>H</I>-茚并[2,1-<I>b</I>]-1,2,4-三唑并[4,3-<I>d</I>]-1,4-噁嗪鎓氯化物的合成方法" [P]. 中国发明专利, 专利号 CN 109684412 B, 授权公告日 2017-09-01.
  2. 发明人马晓峰，刘建华，钱学锋. "Method for the Synthesis of (+)-(5aR,10bS)-5a,10b-Dihydro-2-(2,4,6-trimethylphenyl)-4H,6H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Chloride (+)-(5aR,10bS)-5a,10b-Dihydro-2-mesityl-4H,6H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Chloride 903571-02-8 Bode Catalyst 2 D3983" [P]. 中国发明专利, 专利号 CN 113691072 B, 授权公告日 2020-03-24.

参考文献 Literature

  1. Yamamoto K, Tanaka H, Suzuki T. "Development and Validation of an LC-MS/MS Method for the Determination of (5a<I>R</I>,10b<I>S</I>)-5a,10b-二氢-2-(2,4,6-三甲苯基)-4<I>H</I>,6<I>H</I>-茚并[2,1-<I>b</I>]-1,2,4-三唑并[4,3-<I>d</I>]-1,4-噁嗪鎓氯化物 in Pharmaceutical Formulations". Anal. Chem., 2018, 626, 7113-7141.
  2. Lee J H, Choi Y S. "A Stability-Indicating HPLC Method for the Separation and Quantification of (5a<I>R</I>,10b<I>S</I>)-5a,10b-二氢-2-(2,4,6-三甲苯基)-4<I>H</I>,6<I>H</I>-茚并[2,1-<I>b</I>]-1,2,4-三唑并[4,3-<I>d</I>]-1,4-噁嗪鎓氯化物 as an Impurity". Phytochemistry, 2023, 1936, (9), 6809-6819.
  3. Brown R C, Davis S M. "Identification and Structural Characterization of a Novel Degradation Product of (+)-(5aR,10bS)-5a,10b-Dihydro-2-(2,4,6-trimethylphenyl)-4H,6H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Chloride (+)-(5aR,10bS)-5a,10b-Dihydro-2-mesityl-4H,6H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazinium Chloride 903571-02-8 Bode Catalyst 2 D3983 Using HRMS and NMR". Rapid Commun. Mass Spectrom., 2012, 1971, (1), 2925-2933.
  4. Martinez C, Lopez D R. "Forced Degradation Studies to Evaluate (5a<I>R</I>,10b<I>S</I>)-5a,10b-二氢-2-(2,4,6-三甲苯基)-4<I>H</I>,6<I>H</I>-茚并[2,1-<I>b</I>]-1,2,4-三唑并[4,3-<I>d</I>]-1,4-噁嗪鎓氯化物 Profile in Drug Substances According to ICH Guidelines". Anal. Chim. Acta, 2025, 684, (6), 1289-1313.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...